Is BioAge Labs Inc. (BIOA) a Buy, Sell, or Hold?
BioAge Labs Inc.
NASDAQ:BIOA
$22.594 USD
-$0.19 (-0.82%)
- Volume
- 312.16K
- Average Volume
- 512.67K
- Market Capitalization
- $850.66M
- P/E Ratio
- -9.41
- Dividend Yield
- 0.00%
- Price Target
- $40.00
- Year High
- $25.96
- Year Low
- $4.11
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $24.76
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Kristen Fortney |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | BIOA |
| CUSIP | 09077V100 |
| CIK | 0001709941 |
| Web | https://bioagelabs.com |
| Phone | 510 806 1445 |
| Currency | USD |
| Employees | 62 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 24.76 |
| Quick Ratio | 24.76 |
| Cash Ratio | 15.28 |
Sales & Book Value
| Annual Sales | $9M |
| Price / Sales | 82.46 |
| Cash Flow | -2.09 |
| Price / Cash Flow | -9.60 |
| Price / Book | 2.53 |
Price Target and Rating
| Average Stock Price Forecast | $40.00 |
| High Stock Price Forecast | $62.00 |
| Low Stock Price Forecast | $23.00 |
| Forecast Upside/Downside | -43.51% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 3 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.24 |
| Trailing P/E Ratio | -9.41 |
| PEG Ratio | 0.55 |
| P/E Growth | 0.55 |
| Net Income | $-80.6M |
| Net Margin | -871.75% |
| Pretax Margin | -871.75% |
| Return on Equity | -29.40% |
| Return on Assets | -22.62% |
Financials Score
| AltmanZ Score | 25.72 |
| Piotroski Score | 3.00 |
| Working Capital | 376.03M |
| Total Assets | 397.65M |
| Ebit | -89.45M |
| Market Cap | 820.2M |
| Total Liabilities | 18.53M |
Poll Results
About BioAge Labs Inc. (NASDAQ:BIOA) Stock
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug ... targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
2026-06-16 08:00:00
Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk factors
2026-06-16 08:00:00
Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk factors Primary endpoint is percent change in high-sensitivity C-reactive protein (hsCRP); trial designed to support optimal dose selection for Phase 3 Trial builds on previously reported Phase 1 results in which BGE-102 achieved potential best-in-class hsCRP reductions and was well tolerated across all dose levels Topline data anticipated in the second half of 2026 EMERYVILLE, Calif.
2026-06-08 16:58:30
BioAge Labs, Inc. (BIOA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
2026-06-06 08:05:05
BioAge Labs NASDAQ: BIOA executives used a fireside chat at the Jefferies 2026 Global Healthcare Conference to outline the company's plans for BGE-102, its lead NLRP3 inhibitor, with near-term readouts expected in cardiovascular risk and diabetic macular edema.
BioAge Labs to Present at Upcoming Investor Conferences
2026-05-22 09:00:00
EMERYVILLE, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:
2026-05-13 07:54:40
Pre-Market Stock Futures: Futures are trading mixed on Wednesday, after a rough day for technology stocks and the Nasdaq. The combination of the prospect of a longer struggle with Iran, and higher inflation, which soared to 3.8% annually, the highest since May 2023, while the core number, which is less food and energy, rose to... Here Are Wednesday's Top Wall Street Analyst Research Calls: Advanced Micro Devices, Akamai Technologies, HEICO, Johnson and Johnson, MasTec, MercadoLibre, Sandisk, Snap, and More
2026-05-08 20:31:16
BioAge Labs, Inc. (BIOA) Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease Transcript
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials
2026-05-08 16:02:37
BioAge Labs NASDAQ: BIOA used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant inhibitor of the NLRP3 inflammasome that the company is developing across cardiovascular and retinal disease. Management highlighted phase I clinical results, plans for near-term proof-of-concept studies, and the rationale for pursuing inflammation as a therapeutic target.
Frequently Asked Questions
-
What is the current BioAge Labs Inc. (BIOA) stock price?
-
BioAge Labs Inc.(NASDAQ:BIOA) stock price is $22.594 in the last trading session. During the trading session, BIOA stock reached the peak price of $25.955 while $4.11 was the lowest point it dropped to. The percentage change in BIOA stock occurred in the recent session was --0.82% while the dollar amount for the price change in BIOA stock was -$-0.19.
-
BIOA's industry and sector of operation?
-
The NASDAQ listed BIOA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BIOA?
-
Dov A. Goldstein | Chief Financial Officer
Eric Morgen | Co-Founder, Chief Operating Officer & Director
Kristen Fortney | Co-Founder, Chief Executive Officer, President, Treasurer, Secretary & Director
Paul D. Rubin | Chief Medical Officer & Executive Vice President of Research
Peng Leong | Chief Business Officer & Therapeutic Area Head of Brain Aging -
How many employees does BIOA have?
-
Number of BIOA employees currently stands at 62. BIOA operates from 5885 Hollis Street, Emeryville, CA 94608, US.
-
Link for BIOA official website?
-
Official Website of BIOA is: https://bioagelabs.com
-
How do I contact BIOA?
-
BIOA could be contacted at phone #510 806 1445 and can also be accessed through its website. BIOA operates from 5885 Hollis Street, Emeryville, CA 94608, US.
-
How many shares of BIOA are traded daily?
-
The average number of BIOA shares traded daily for last 3 months was 512.67K.
-
What is the market cap of BIOA currently?
-
The market value of BIOA currently stands at $850.66M with its latest stock price at $22.594